Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-01-13 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于公司董事长增持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the increase in shareholding by the company's chairman, including details of the share purchase, the source of funds, and compliance with relevant laws. It is a notification of a director's personal share transaction rather than a financial report, meeting, or other corporate filing. The content matches the definition of Director's Dealing (DIRS). The document length is short and focused solely on this transaction, confirming it is not a broader report or announcement type.
2021-01-13 Chinese
关于对控股子公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding a capital increase in its controlling subsidiary, Xinxiang Shuanglu Pharmaceutical Co., Ltd., which is a related party transaction. The text details the board meeting resolutions, the amount of capital increase, the shareholding structure before and after the increase, financial data of the related parties, and independent directors' opinions. It is a formal disclosure of a financing transaction involving capital injection into a subsidiary. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a proxy statement, voting result, or management change announcement. It is a capital/financing update about the company's investment in its subsidiary. The document length is 4799 characters, which is sufficient for a detailed announcement but not a full annual or interim report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-01-08 Chinese
关于第二大股东部分股权质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's second largest shareholder. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and the purpose of the pledge. It includes tables summarizing the pledge details and cumulative pledge status. The document is titled as an announcement and contains no financial statements or detailed financial analysis. It is a regulatory disclosure about share pledge activity, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short (2257 characters), and it is a standalone announcement rather than a report or presentation.
2021-01-08 Chinese
第七届监事会第十二次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting regarding a capital increase in a subsidiary company. It includes details about the meeting date, attendance, voting results, and compliance with company law and internal rules. The content focuses on management decisions and corporate governance matters rather than financial results, audit opinions, or shareholder voting outcomes. It is not a full financial report, earnings release, or proxy solicitation. The document is an announcement of a board/management decision related to corporate governance and internal company affairs. Therefore, it fits best under the category 'Board/Management Information (MANG)'. The document length is short and does not contain financial statements or detailed financial data, supporting this classification.
2021-01-08 Chinese
第七届董事会第十六次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution regarding an increase in capital investment in a subsidiary company. It details the board meeting date, attendance, voting results, and the specifics of the capital increase and related party transactions. It does not contain financial statements or detailed financial performance data. The document is short (1149 characters) and serves as a formal announcement of a board decision rather than a full report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-01-08 Chinese
独立董事关于公司对控股子公司增资暨关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding a capital increase in a controlling subsidiary and related party transaction. It discusses the board meeting resolution, the use of company funds for the investment, compliance with company law and articles of association, and the fairness of the transaction. The document is a formal opinion on a specific corporate action rather than a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it contains substantive content and opinion. The document fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure related to corporate governance and related party transactions but does not fit other more specific categories like MANG or CAP because it is an independent opinion rather than a management announcement or capital update per se.
2021-01-08 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.